Cancer remains one of the leading health challenges in Kenya, contributing to approximately 7% of annual deaths, with an estimated 32,000 lives lost and 44,000 new cases diagnosed each year.
The high mortality rate is attributed to late-stage diagnoses, limited access to screening programs, and gaps in treatment infrastructure. In response to this pressing issue, Aga Khan University Hospital, Nairobi (AKUHN) has partnered with AstraZeneca to expand access to BRCA1/2 genetic testing in Kenya.
The partnership, announced on Friday, 28 November 2025, aims to strengthen cancer detection and improve treatment outcomes, particularly for breast and ovarian cancers, which are closely linked to genetic mutations in the BRCA1 and BRCA2 genes. By making BRCA1/2 testing more accessible and affordable, the initiative hopes to improve early diagnosis and precision treatment for patients at risk.
AstraZeneca’s oncology division is known for its research in cancer treatment, particularly in tumor biology, resistance mechanisms, and DNA damage response. Their collaboration with AKUHN complements the hospital’s existing cancer program, which includes early detection, advanced diagnostics, chemotherapy, radiotherapy, and palliative care.
According to Dr. Khomotso Mashilane, AstraZeneca’s Medical Director for Africa, this partnership represents a significant step towards providing equitable, high-quality cancer care in Kenya. “By offering more affordable access to BRCA testing, we aim to empower healthcare professionals to make better-informed decisions about patient care and treatment,” Dr. Mashilane stated.
Prof. Shahin Sayed, Chair of Laboratory Medicine at AKUHN, emphasized the importance of accurate diagnostics in guiding treatment and improving survival rates. He explained that BRCA1/2 testing is crucial for identifying individuals at high risk of developing breast, ovarian, pancreatic, or prostate cancer.
What Are BRCA1 and BRCA2?
BRCA1 and BRCA2 are genes responsible for repairing damaged DNA. Mutations in these genes significantly increase the risk of several cancers, particularly breast and ovarian cancer, and often result in earlier onset. These mutations are inherited, meaning that individuals who have a family history of breast cancer, ovarian cancer, or related cancers should consider BRCA testing.
The testing can be performed using either blood or saliva samples, and the results can guide healthcare providers in selecting targeted therapies and preventive measures. Early detection and intervention are key in improving outcomes for patients, allowing for earlier treatment and better chances of survival.
“Making BRCA1/2 testing more affordable is a game-changer for many Kenyan families,” said Prof. Sayed. “The ability to diagnose and treat cancer earlier can make a significant difference in patient survival rates, and we are proud to be part of this effort.”
Why This Partnership Matters
The collaboration between Aga Khan University Hospital and AstraZeneca is particularly significant given the limited access to cancer testing and treatment in many parts of Kenya. High costs, lack of awareness, and limited healthcare infrastructure have prevented many patients from receiving timely care.
By addressing these challenges, the partnership aims to not only improve access to BRCA testing but also enhance overall cancer care in the country.
This initiative aligns with Kenya’s growing efforts to tackle cancer and other non-communicable diseases. With ongoing support from organizations like AstraZeneca, there is hope that more Kenyans will be able to access the life-saving care they need.
